Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging Phase IIb trial of GSK189075 vs pioglitazone vs placebo in type 2 diabetes mellitus
2006-004694-97Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remogliflozin etabonate in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by GSK. Primary endpoint: HbA1c reduction at 12 weeks. Started Nov 2006; status: completed.
02
Drugs
remogliflozin etabonate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-004694-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004694-97.